Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfasalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.76 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.76 |
| ▸ | USP2 | O75604 | 1/20 | 0.76 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | CA1 | P00915 | 1/20 | 0.76 |
| ▸ | CA2 | P00918 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | MMP1 | P03956 | 1/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | CASP1 | P29466 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfasalazine SCHEMBL15673025 | 0.89 | SLC7A11 (0.85) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL4515 | 0.87 | SLC7A11 (1.00) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL29861725 | 0.87 | SLC7A11 (1.00) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL18256143 | 0.87 | SLC7A11 (1.00) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL4514 | 0.87 | SLC7A11 (1.00) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL10289061 | 0.87 | SLC7A11 (1.00) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL487664 | 0.87 | SLC7A11 (1.00) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL5664970 | 0.87 | SLC7A11 (1.00) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL31174674 | 0.87 | SLC7A11 (1.00) | SLC7A11MEN1ABCC3ABCC4USP2 | |
| Sulfasalazine SCHEMBL21055748 | 0.86 | SLC7A11 (0.98) | SLC7A11MEN1ABCC3ABCC4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100203146-A1 | INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRITIS | CALLISTO PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | US | claimed |
| WO-2010091381-A3 | AN INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRTIS | CALLISTO PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100203146-A1 | INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRITIS | CALLISTO PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203146-A1 | INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRITIS | CALLISTO PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010091381-A2 | AN INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRTIS | CALLISTO PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091381-A2 | AN INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRTIS | CALLISTO PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20080175880-A1 | Pyridoxal-5-Phosphate And Stent For The Treatment And Prevention Of Atherosclerosis And Restenosis | MEIDCURE INTERNATIONAL INC. (BB) | 2008-07-24 | — | — | US | disclosed |
| EP-1804808-A1 | PYRIDOXAL-5-PHOSPHATE AND STENT FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND RESTENOSIS | Medicure International Inc. (BB) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006056038-A1 | PYRIDOXAL-5-PHOSPHATE AND STENT FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND RESTENOSIS | MEDICURE INTERNATIONAL INC. (CA) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203146-A1 | INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRITIS | ASGR1, TNF, TPMT | SLC7A11 151/4885MEN1 4560/4885ABCC3 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.